This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Biotech Trades for Second Half of 2011

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Gilead Sciences (GILD - Get Report)
The event: Phase III data on the Quad, a new four-in-one combination pill for HIV.
The timeline: Data from two phase III studies (Quad vs. Atripla and Quad vs. boosted Reyataz and Truvada) are due in the second half of the year.
The stakes: The long-term growth of Gilead's market-leading HIV drug franchise. The Quad is a single pill made up four Gilead drugs: Currently approved Viread and Emtriva plus two experimental drugs elvitegravir and cobicistat. If approved, the Quad could extend Gilead's competitive advantage in HIV therapy especially as generic competition looms in the 2017-2018 time frame. The Quad will also be more profitable for Gilead since it will likely replace Atripla, a three-in-one combination pill that includes one drug from Bristol-Myers Squibb.

9 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BPAX $55.05 -1.24%
TSPT $27.63 2.30%
EXEL $3.29 0.00%
GILD $112.46 0.00%
ONTY $3.36 0.00%

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs